|Mr. Jerome B. Durso||Pres & CEO||853.17k||N/A||1968|
|Dr. Mark Pruzanski||Founder, Advisor & Director||1.3M||N/A||1968|
|Dr. Christian Weyer||Exec. VP of R&D||679.45k||N/A||1970|
|Mr. Rocco Venezia||Chief Accounting Officer, Treasurer & Acting CFO||N/A||N/A||N/A|
|Ms. Lisa M. DeFrancesco||Sr. VP of Corp. Affairs & Investor Relations||N/A||N/A||1979|
|Mr. Jared M. Freedberg||Gen. Counsel & Sec.||N/A||N/A||1969|
|Mr. David Ford||Chief HR Officer||N/A||N/A||1970|
|Dr. Gail Cawkwell||Sr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical Officer||N/A||N/A||1963|
|Ms. Linda M. Richardson||Exec. VP & Chief Commercial Officer||N/A||N/A||1964|
|Mr. Bryan Ball||Chief Quality Officer||N/A||N/A||1970|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 5.